Interleukin-2: Clinical applications

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 7, 2002, Pages 12-17

  Atkins, Michael B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DACARBAZINE; GAMMA INTERFERON; INTERLEUKIN 2; TAMOXIFEN; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DEATH; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; FEVER; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; MELANOMA; METASTASIS; NAUSEA; PRIORITY JOURNAL; REVIEW; SEPSIS;

EID: 0036276002     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.33077     Document Type: Article

References (63)

1. Selective in vitro growth of T-lymphocytes from normal bone marrows
2. Lymphocyte responses and cytokines
3. Structure and expression of a cloned cDNA for human interleukin-2
4. Biological activity of recombinant interleukin-2 produced in Escherichia coli
5. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission
6. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
7. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma
8. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with malignant melanoma: An Eastern Cooperative Oncology Group study
9. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
10. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2
11. A phase II study of interleukin-2 and lymphokine activated killer (LAK) cells in patients with metastatic malignant melanoma
12. Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study
13. The modified group C experience - Phase III randomized trials of IL-2 vs. 1L-2/LAK in advanced renal cell carcinoma and advanced melanoma
14. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
15. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients between 1985 and 1993
16. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update
17. The clinical toxicities of high-dose interleukin-2
18. Biologic therapy with interleukin-2: Clinical applications: Principles of administration and management of side effects
19. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock
20. Interleukin-2: Clinical applications. Melanoma
21. Long-term survival after continuous infusion interleukin-2
22. A phase I study of prolonged continuous infusion of low dose recombinant IL-2 in mrlanoma and renal cell cancer. Part I. Clinical aspect
23. Phase II study of intermittent continuous infusion of low-dose recombinant IL-2 in melanoma and renal cell cancer
24. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients
25. Efficacy of interleukin-2 in the treatment of metastatic melanoma - Systemic review and metastasis-analysis
26. Phase III randomized trial of cisplatin, vinblastine, and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha-2b (IFN) versus CVD in patients (pts) with metastatic melanoma
27. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
28. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma
29. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma
30. Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: A pilot study
31. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: A pilot study
32. High dose recombinant interleukin-2 and acute myeloid leukemia in relapse
33. Interleukin-2 may induce prolonged remissions in advanced myelogenous leukemia
34. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: Update with 20 cases
35. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukaemia
36. Phase II study of subcutaneous rHu IL-2 in patients with acute myelogenous leukaemia in partial or complete second remission and partial relapse
37. Impact of recombinant IL-2 (rIL-2) after autologous BMT in 50 patients with CR1 acute leukaemia
38. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
39. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report
40. Chemoimmunotherapy in the systemic treatment of advanced renal carcinoma
41. Interleukin-2-based therapy for metastatic renal cell cancer: The Cytokine Working Group experience, 1989-1997
42. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: Five-year follow-up of the Cytokine Working Group Study
43. Renal cell carcinoma: Current status and future plans
44. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma
45. In-patient continuous infusion IL-2 in 788 patients with cancer. The National Biotherapy Study Group experience
46. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: A phase II trial of the cancer biotherapy research group (formerly the National Biotherapy Study Group)
47. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma
48. Phase I study of weekly 24-hour infusions of recombinant human IL-2
49. Low dose subcutaneous IL-2 in advanced human malignancy. A phase II outpatient study
50. Biological monitoring of low-dose IL-2 in humans: Soluble IL-2 receptors, cytokines and cell surface phenotypes
51. Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: Anti-tumor activity and immunomodulatory effects
52. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma
53. Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma
54. Sequential chemoimmunotherapy in the treatment of metastatic melanoma
55. Development and results of biochemotherapy in metastatic melanoma: The University of Texas M. D. Anderson Cancer Center experience
56. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group
57. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine (CVD), interleukin-2 (IL-2) and interferon alpha-2b (IFN) in patients with metastatic melanoma
58. Phase II trial of concurrent biochemotherapy (c-BC) with decrescendo interleukin-2 (d-IL-2), tamoxifen (T), and G-CSF support in patients with metastatic melanoma (MM)
59. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma
60. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma
61. Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen
62. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha- interferon and tamoxifen for advanced metastatic melanoma: A pilot study
63. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma